Eppendorf Posts Successful 2012

The Eppendorf Group performed well in fiscal year 2012, generating sales of more than €500 million for the first time. Sales increased by 8.9 percent year on year to €520.2 million (prior year: €477.7 million). Organic growth, after adjustment for currency effects and acquisitions, was 4.0 percent. Income from operations (EBIT) improved by 11.5 percent to €101.5 million (prior year: €91 million). Net income in 2012 rose to €70.6 million, which is 14 percent over fiscal 2011. In order to keep on developing its product portfolio, the Group increased its investments in research and development in 2012 by 10.7 percent to a total of €27.5 million (prior year: €24.9 million). Eppendorf also invested in expanding its international sales footprint and opened new sales companies in Korea and Russia.

“In view of the challenging market environment for our industry, we can be satisfied with how we did in fiscal 2012,” said Dr. Dirk Ehlers, CEO of Eppendorf AG. “In 2012 we expanded our Cell Handling application area by acquiring the DASGIP Group, an important addition for us. Continuous development of our product portfolio, whether through research and development or through acquisitions, will remain a focus of our activities in 2013,” added Ehlers.